Novo Nordisk's IDegLira shows superior glycemic control and weight loss

Danish insulin giant Novo Nordisk (NOV: N) has presented positive new Phase III data from the investigational therapy IDegLira (insulin degludec [Tresiba]/liraglutide injection [Victoza]) at the World Diabetes Congress of the International Diabetes Federation.

The DUAL II trial shows that, in comparison with insulin degludec, IDegLira achieved superior control of blood sugar levels (HbA1c). Improved fasting and postprandial plasma glucose levels were seen with IDegLira throughout the day and across meals, while providing significant weight loss for adults with type 2 diabetes uncontrolled on basal insulin. The rate of hypoglycemia was low in both treatment groups, even with a significant difference in HbA1c reduction with IDegLira. This trial was designed to evaluate the contribution of the liraglutide component of IDegLira on glycemic control.

IDegLira is the first-ever once-daily, single administration combination of a long-acting basal insulin and glucagon-like peptide 1 (GLP-1) analogue being developed by Novo Nordisk, which filed for European regulatory approval of the product in the spring (The Pharma Letter May 31).